|
gptkbp:instanceOf
|
gptkb:gene_therapy
gptkb:immunotherapy
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
specialized centers
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XL08
|
|
gptkbp:blackBoxWarning
|
cytokine release syndrome
neurological toxicities
|
|
gptkbp:brand
|
gptkb:Yescarta
|
|
gptkbp:CASNumber
|
gptkb:1805230-56-4
|
|
gptkbp:cost
|
high
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Kite_Pharma
|
|
gptkbp:indication
|
relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
genetically modified autologous T cells
targets CD19 antigen
|
|
gptkbp:pregnancyCategory
|
not assigned
|
|
gptkbp:prescriptionRequired
|
https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125643s019lbl.pdf
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297599
gptkb:DB13963
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
cytokine release syndrome
neurological toxicities
|
|
gptkbp:source
|
autologous T cells
|
|
gptkbp:storage
|
cryopreserved
|
|
gptkbp:target
|
gptkb:CD19
|
|
gptkbp:type
|
chimeric antigen receptor T-cell therapy
|
|
gptkbp:UNII
|
6H4E9E3A5T
|
|
gptkbp:usedFor
|
gptkb:large_B-cell_lymphoma
gptkb:primary_mediastinal_large_B-cell_lymphoma
diffuse large B-cell lymphoma
high grade B-cell lymphoma
transformed follicular lymphoma
|
|
gptkbp:bfsParent
|
gptkb:CAR-T_cell_therapies
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Axicabtagene ciloleucel
|